Your browser is no longer supported. Please, upgrade your browser.
INSM Insmed Incorporated daily Stock Chart
Insmed Incorporated
Index- P/E- EPS (ttm)-2.65 Insider Own0.80% Shs Outstand96.63M Perf Week-5.10%
Market Cap3.30B Forward P/E- EPS next Y-1.94 Insider Trans-9.05% Shs Float94.68M Perf Month19.62%
Income-241.90M PEG- EPS next Q-0.61 Inst Own98.28% Short Float12.27% Perf Quarter15.04%
Sales163.90M P/S20.16 EPS this Y28.70% Inst Trans16.24% Short Ratio13.87 Perf Half Y79.10%
Book/sh4.19 P/B7.81 EPS next Y26.00% ROA-31.50% Target Price45.25 Perf Year74.80%
Cash/sh6.36 P/C5.15 EPS next 5Y- ROE-82.20% 52W Range12.09 - 35.32 Perf YTD37.10%
Dividend- P/FCF- EPS past 5Y-10.40% ROI-38.20% 52W High-5.52% Beta2.49
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin79.50% 52W Low176.01% ATR1.64
Employees435 Current Ratio9.00 Sales Q/Q41.70% Oper. Margin- RSI (14)64.48 Volatility4.74% 5.28%
OptionableYes Debt/Eq0.90 EPS Q/Q21.30% Profit Margin- Rel Volume0.45 Prev Close32.74
ShortableYes LT Debt/Eq0.90 EarningsAug 06 BMO Payout- Avg Volume837.36K Price33.37
Recom1.90 SMA2011.22% SMA5017.30% SMA20033.03% Volume367,880 Change1.92%
Sep-03-19Initiated Goldman Buy $30
Apr-09-19Reiterated H.C. Wainwright Buy $43 → $52
Feb-15-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $40
Jan-17-19Upgrade Goldman Neutral → Buy
Jan-02-19Initiated Canaccord Genuity Buy $20
Aug-06-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-23-18Initiated Goldman Neutral $32
Apr-23-18Upgrade Credit Suisse Neutral → Outperform
Mar-21-18Initiated Morgan Stanley Overweight $39
Jan-18-18Initiated Credit Suisse Neutral $31
Sep-05-17Reiterated Evercore ISI Outperform $28 → $40
Aug-17-17Initiated Evercore ISI Outperform $28
Jul-11-17Initiated Robert W. Baird Outperform $23
Mar-15-16Initiated Stifel Buy $23
Nov-09-15Downgrade UBS Buy → Neutral $35 → $18
Oct-06-15Reiterated H.C. Wainwright Buy $30 → $35
Jun-09-15Initiated Citigroup Neutral $27
Mar-26-14Reiterated HC Wainwright Buy $25 → $30
Jan-06-14Reiterated UBS Buy $17.50 → $31
Nov-11-13Initiated HC Wainwright Buy $25
Sep-24-20 08:30AM  
Sep-16-20 05:11PM  
Sep-15-20 08:30AM  
Sep-09-20 04:05PM  
Sep-08-20 08:30AM  
Sep-07-20 12:25PM  
Sep-04-20 08:00AM  
Sep-03-20 08:30AM  
Sep-01-20 08:30AM  
Aug-26-20 01:11PM  
Aug-20-20 04:01PM  
Aug-14-20 08:30AM  
Aug-11-20 12:33PM  
Aug-07-20 08:00AM  
Aug-06-20 10:35AM  
Aug-03-20 12:30PM  
Jul-30-20 12:33PM  
Jul-28-20 08:30AM  
Jul-27-20 08:30AM  
Jul-24-20 08:25AM  
Jul-15-20 01:15PM  
Jul-07-20 08:00AM  
Jul-06-20 08:00AM  
Jun-29-20 08:30AM  
Jun-28-20 05:26PM  
Jun-24-20 04:01PM  
Jun-23-20 04:03PM  
Jun-19-20 11:58AM  
Jun-08-20 08:00AM  
Jun-05-20 08:00AM  
May-26-20 08:00AM  
May-25-20 01:15PM  
May-20-20 09:29AM  
May-19-20 09:47AM  
May-07-20 10:46AM  
May-05-20 08:00AM  
May-04-20 04:01PM  
May-01-20 03:01PM  
Apr-30-20 09:05AM  
Apr-29-20 09:47AM  
Apr-23-20 12:32PM  
Apr-20-20 08:00AM  
Apr-13-20 09:12AM  
Apr-07-20 03:33PM  
Apr-03-20 08:00AM  
Apr-02-20 08:00AM  
Mar-17-20 08:48AM  
Mar-16-20 04:01PM  
Mar-05-20 08:00AM  
Mar-04-20 08:00AM  
Mar-02-20 04:56PM  
Feb-27-20 08:13AM  
Feb-26-20 08:00AM  
Feb-25-20 08:55AM  
Feb-20-20 08:15AM  
Feb-19-20 08:00AM  
Feb-10-20 08:00AM  
Feb-05-20 07:43AM  
Feb-04-20 10:20AM  
Feb-03-20 04:14PM  
Jan-30-20 08:00AM  
Jan-09-20 08:00AM  
Jan-03-20 04:05PM  
Jan-01-20 02:24PM  
Dec-07-19 05:50PM  
Dec-03-19 04:05PM  
Nov-18-19 03:29AM  
Nov-14-19 08:00AM  
Nov-05-19 08:00AM  
Nov-04-19 04:05PM  
Nov-02-19 08:32AM  
Oct-31-19 09:26AM  
Oct-30-19 08:55AM  
Oct-27-19 04:14PM  
Oct-23-19 08:00AM  
Oct-21-19 10:54AM  
Oct-17-19 03:30PM  
Oct-07-19 04:05PM  
Sep-18-19 09:11AM  
Sep-05-19 04:05PM  
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHAROKY MELVIN MDDirectorSep 15Sale30.3310,000303,3009,900Sep 16 06:56 PM
SHAROKY MELVIN MDDirectorSep 15Sale31.039,900307,197236,890Sep 16 06:56 PM
SHAROKY MELVIN MDDirectorSep 14Sale30.701003,07019,900Sep 16 06:56 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerAug 12Option Exercise11.874,46552,99639,227Aug 13 04:11 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerAug 12Sale28.804,465128,57835,227Aug 13 04:11 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerAug 11Option Exercise6.963,76126,17738,988Aug 13 04:11 PM
Schaeffer Orlov S NicoleChief People Strategy OfficerAug 11Sale30.073,761113,09335,227Aug 13 04:11 PM
SORIANO JOHNChief Compliance OfficerAug 10Option Exercise13.9152,046723,96077,259Aug 12 05:17 PM
SORIANO JOHNChief Compliance OfficerAug 10Sale30.2952,0461,576,47325,213Aug 12 05:17 PM
GOLL JOHNChief Accounting OfficerNov 18Option Exercise12.5825,000314,50032,322Nov 20 04:10 PM
GOLL JOHNChief Accounting OfficerNov 18Sale20.0425,000501,0007,322Nov 20 04:10 PM